AstraZeneca says detained China head has lawyer

AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about the case, its CEO said on Tuesday.
AstraZeneca says China has detained a senior executive
The company believes Chinese authorities are probing allegations that two current and two former employees had illegally imported cancer drugs.
Pharma Giant AstraZeneca Takes China Probes 'Very Seriously'
British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention of its China boss.
AstraZeneca CEO says detained China chief has a lawyer but 'we have no information'
AstraZeneca's CEO said on Tuesday that the company's China president Leon Wang, who last month was detained by Chinese authorities, has a lawyer he is in touch with, but "we have no information as a company".
AstraZeneca Says Current, Former Executives Involved in China Probe
Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe into alleged breaches of laws around drug importation and data privacy, the company said.
AstraZeneca talks up US growth as China problems fester
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drugmaker’s share price.
AstraZeneca's China chief in custody, believes unrelated to insurance probe
AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not know the reason, it did not believe it was linked to a large health insurance fraud case involving the company.
AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
FiercePharma2d
AstraZeneca CEO defends corporate oversight, $80B revenue target amid China probes
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
Benzinga.com2d
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a high-teens percentage, ...
BioSpace2d
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Investopedia on MSN9d
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an ...
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
BioSpace1d
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...
Outsourcing-pharma15h
AstraZeneca doubles down on US manufacturing with $3.5 billion investment
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
FTSE 100 Live 12 November: Vodafone and AstraZeneca results fail to revive shares, Metro Bank fined £16m
DCC shares have jumped 17% in the FTSE 100 index after the Dublin-based conglomerate announced plans to focus on its energy ...